Literature DB >> 11867956

Elevated plasma vascular endothelial growth factor levels in non-diabetic predialysis uraemia.

Steven J Harper1, Lee Downs, Charles R V Tomson, Jeremy S J Dwight, Colin Bolton.   

Abstract

Chronic renal impairment is associated with increased vascular morbidity and mortality. The pathogenesis of this aggressive vascular pathology is unknown but believed to be multi-factorial in origin. There is accumulating in vivo and in vitro evidence to suggest that the vascular endothelium is dysfunctional in uraemia, including the propensity of endothelial cells to produce VEGF in response to acidosis. There is also preliminary data to suggest abnormally increased endothelial permeability in uraemia. To investigate the potential abnormal circulating levels of VEGF in uraemia, EDTA plasma samples were collected from 20 non-diabetic predialysis patients and matched controls. Free plasma VEGF levels were detected using a commercially available ELISA kit. There were significantly higher plasma levels of VEGF predialysis group (median 351 pg/ml, range 70-636 pg/ml) compared to matched controls (median 125.5 pg/ml, range 22-450 pg/ml), p < 0.002. In conclusion, free plasma VEGF levels are high in chronic renal impairment. We hypothesise that this potent growth and permeability factor may contribute to the endothelial dysfunction of uraemia. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11867956     DOI: 10.1159/000049071

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  6 in total

1.  Chronic kidney disease worsens sepsis and sepsis-induced acute kidney injury by releasing High Mobility Group Box Protein-1.

Authors:  Asada Leelahavanichkul; Yuning Huang; Xuzhen Hu; Hua Zhou; Takayuki Tsuji; Richard Chen; Jeffrey B Kopp; Jürgen Schnermann; Peter S T Yuen; Robert A Star
Journal:  Kidney Int       Date:  2011-08-10       Impact factor: 10.612

2.  Cholecalciferol supplementation and angiogenic markers in chronic kidney disease.

Authors:  Jaskiran Kaur; Kajal Kamboj; Ashok Kumar Yadav; Prabhjot Kaur; Vivek Kumar; Vivekanand Jha
Journal:  PLoS One       Date:  2022-06-03       Impact factor: 3.752

3.  Pre-existing renal disease promotes sepsis-induced acute kidney injury and worsens outcome.

Authors:  Kent Doi; Asada Leelahavanichkul; Xuzhen Hu; Karen L Sidransky; Hua Zhou; Yan Qin; Christoph Eisner; Jürgen Schnermann; Peter S T Yuen; Robert A Star
Journal:  Kidney Int       Date:  2008-07-16       Impact factor: 10.612

4.  Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease. Associations with laboratory findings, comorbidities, and medications.

Authors:  Ismail Erturk; Fatih Yesildal; Ramazan Acar; Taner Ozgurtas; Kenan Saglam
Journal:  Saudi Med J       Date:  2018-06       Impact factor: 1.484

Review 5.  Role of Receptor Tyrosine Kinase Signaling in Renal Fibrosis.

Authors:  Feng Liu; Shougang Zhuang
Journal:  Int J Mol Sci       Date:  2016-06-20       Impact factor: 5.923

6.  Plasma N-Terminal Probrain Natriuretic Peptide, Vascular Endothelial Growth Factor, and Cardiac Troponin I as Novel Biomarkers of Hypertensive Disease and Target Organ Damage in Cats.

Authors:  E S Bijsmans; R E Jepson; C Wheeler; H M Syme; J Elliott
Journal:  J Vet Intern Med       Date:  2017-04-07       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.